Fast Market Research announces the availability of the new GlobalData report, "EpiCast Report: Heart Failure - Epidemiology Forecast to 2025", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 06/10/2016 -- Heart Failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. HF commonly occurs in people above 50 years of age, and severity increases progressively with age. Symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF, the symptoms develop gradually. Due to the chronic nature of cardiovascular diseases, many of the risk factors for HF, such as chronic obstructive pulmonary disease (COPD) and anemia, are also comorbid conditions.
Get More Details on this Report and a Full Table of Contents at EpiCast Report: Heart Failure - Epidemiology Forecast to 2025
In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,094,344 cases in 2015 to 1,400,377 cases in 2025 at an Annual Growth Rate (AGR) of 2.80%. In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of chronic HF will increase from 13,756,453 cases in 2015 to 16,105,489 cases in 2025 at an AGR of 1.71%. The US will have the highest number of diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF among the 7MM throughout the forecast period with 1,052,831 diagnosed incident cases of HF and 6,170,142 diagnosed prevalent cases of chronic HF in 2025. In the 7MM in 2015, 37.59% of the diagnosed prevalent cases of chronic HF are in NYHA Class I, 39.54% in NYHA Class II, 19.11% in NYHA Class III, and 3.75% in NYHA Class IV.
GlobalData epidemiologists utilized comprehensive, country-specific data from national HF registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of HF, as well as the diagnosed prevalent cases of chronic HF. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident and diagnosed prevalent cases of HF. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed incident and diagnosed prevalent cases of HF across these markets.
-The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of HF diagnosed incident and diagnosed prevalent cases segmented by age and sex. Diagnosed incident cases are further segmented by ejection fraction, ventricular dysfunction, acute HF hospitalizations (by worsening HF, advanced HF, de novo HF), re-admissions (within 3 months) post-discharge after acute HF hospitalization, and hospital length of stay for acute HF hospitalization in these seven markets. Diagnosed prevalent cases are further segmented by chronic HF (by ejection fraction), and also classified according to the New York Heart Association (NYHA) functional classes I-IV, and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stages B, C and D in these seven markets.
-The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
-The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Get this Report
The HF EpiCast report will allow you to -
-Develop business strategies by understanding the trends shaping and driving the global HF market.
-Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
-Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
-Identify the percentage of HF diagnosed incident and diagnosed prevalent cases by various clinical segmentations.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
-EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
-EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
-EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024
-Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016
-Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H2, 2015